Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localised prostate cancer shows 100 percent biochemical free recurrence rate more than two years post-surgery
GlobeNewswire
Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with..